Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long‐Term Use of Glucocorticoids
- 7 October 2021
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 73 (11) , 1597-1605
Abstract
Background Glucocorticoids are recommended for short‐term use in rheumatoid arthritis (RA), but many patients remain on long‐term therapy. We evaluated the variability in glucocorticoid prescribing across rheumatologists to inform interventions to limit long‐term glucocorticoid use to the lowest dose necessary. Methods Two cohorts were created using Medicare data 2006‐2015. Using cohort 1 (RA patients on DMARDs), we calculated each rheumatologist’s “provider preference” for glucocorticoids (frequency of use compared to other providers), using ratio of observed to expected number of patients receiving glucocorticoids to account for case‐mix. In cohort 2 (RA patients on stable DMARD therapy) we evaluated whether provider preference for glucocorticoids could independently predict use of ≥5mg/day of glucocorticoids 6‐9 months after DMARD initiation. Results Using Cohort 1 (1,272,644 yearly observations, 385,597 patients) we calculated provider preference among 6,875 rheumatologists (28,936 yearly observations). Provider preference was highly variable, with physicians at the lowest and upper quartiles using glucocorticoids 33% less often (25th percentile) to 31% more often (75th percentile) than expected. In Cohort 2 (155,539 patients on stable DMARD therapy), provider preference was strongly associated with glucocorticoid use ≥5mg/day at 6‐9 months, with predicted probability of use 22% (95% CI 21.7‐22.7) vs. 11% (10.2‐10.9) for a patient seeing a provider in the highest versus lowest quintile of preference. Conclusion Glucocorticoid prescribing for RA varies greatly among rheumatologists; provider preference is one of the strongest predictors of a patient’s long‐term glucocorticoid use. These results raise quality of care concerns and highlight the need for stronger evidence to guide RA treatment.Keywords
Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (1K23AR073931‐01)
This publication has 24 references indexed in Scilit:
- Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)Annals of the Rheumatic Diseases, 2013
- Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case–control analysisAnnals of the Rheumatic Diseases, 2012
- Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune DiseasesJAMA, 2011
- High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2011
- Instrumental variable methods in comparative safety and effectiveness researchPharmacoepidemiology and Drug Safety, 2010
- Evaluating Short-Term Drug Effects Using a Physician-Specific Prescribing Preference as an Instrumental VariableEpidemiology, 2006
- Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease‐modifying antirheumatic drugs, and anti–tumor necrosis factor therapyArthritis & Rheumatism, 2006
- Low‐dose prednisolone in addition to the initial disease‐modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two‐year randomized trialArthritis & Rheumatism, 2005
- Current use of glucocorticoids in patients with rheumatoid arthritis in GermanyArthritis Care & Research, 2005
- Variation among rheumatologists in the use of prednisone and second‐line agents for the treatment of rheumatoid arthritisArthritis & Rheumatism, 1994